GleamWall
中文EN

TKNO Alpha Teknova, Inc.

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1850902 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY15.4%
TTM net income YoY12.3%
TTM EPS YoY9.1%
Revenue 3-yr CAGR7.8%
Net income 3-yr CAGR—

Margins

Gross margin36.4%
Operating margin-32.7%
Net margin-34.8%
FCF margin-13.9%
EBITDA margin-20.1%

Returns

ROE-24.1%
ROA-15.8%
ROIC (approx.)-15.9%
Asset turnover0.45x

Leverage & solvency

Liabilities / assets36.9%
Debt / equity0.22x
Current ratio3.56x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.35x
Accruals ratio-10.3%
Payout ratio—
Capex / revenue1.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$12.70M$12.19M$11.08M$9.98M$10.45M$10.29M$9.79M$9.27M
Cost of revenue$7.88M$7.30M$7.29M$6.74M$7.25M$6.30M$6.79M$7.14M
Gross profit$4.83M$4.88M$3.78M$3.24M$3.21M$3.98M$3.01M$2.13M
R&D expense$581,000$554,000$609,000$522,000$542,000$581,000$552,000$594,000
SG&A expense$4.82M$4.81M$5.06M$5.25M$4.65M$4.93M$5.49M$5.32M
Operating income-$3.21M-$2.89M-$4.30M-$4.61M-$4.02M-$3.39M-$4.96M-$5.63M
Pretax income-$3.46M-$3.14M-$4.51M-$4.82M-$4.21M-$3.55M-$4.62M-$5.76M
Income tax$34,000$30,000$47,000-$62,000$79,000$19,000$22,000-$38,000
Net income-$3.49M-$3.17M-$4.55M-$4.76M-$4.29M-$3.57M-$4.64M-$5.72M
EBITDA-$1.91M-$1.59M-$2.72M-$3.03M-$2.72M-$2.09M-$3.38M-$3.98M
EPS (basic)-0.06-0.06-0.08—-0.08-0.07-0.09—
EPS (diluted)-0.06-0.06-0.08—-0.08-0.07-0.09—
Weighted avg. shares (diluted)53.69M53.63M53.61M—53.52M53.45M53.42M—
Banking
Net interest income-$259,000-$252,000-$219,000-$211,000-$190,000-$165,000-$144,000-$129,000
Balance sheet
Cash & equivalents$6.63M$6.00M$4.31M$5.91M$3.20M$3.28M$3.38M$3.71M
Short-term investments$9.93M$11.43M$13.48M$15.43M$18.91M$20.72M$22.90M$26.69M
Receivables$5.82M$5.41M$5.67M$4.62M$5.13M$5.14M$5.62M$4.31M
Inventory$7.48M$6.91M$6.87M$7.05M$6.91M$7.61M$6.57M$6.80M
Current assets$31.80M$30.82M$31.67M$34.51M$36.56M$38.06M$39.73M$42.78M
PP&E, net$38.09M$39.31M$40.52M$41.73M$42.62M$43.60M$44.73M$45.75M
Intangibles$11.08M$11.37M$11.66M$11.94M$12.23M$12.52M$12.80M$13.09M
Total assets$94.68M$95.88M$98.66M$103.58M$107.62M$110.49M$113.99M$118.77M
Current liabilities$8.93M$6.87M$6.90M$7.54M$6.94M$6.48M$7.04M$11.21M
Short-term debt———$0$0$0$0$4.04M
Long-term debt$13.27M$13.22M$13.17M$13.12M$13.08M$13.03M$12.99M$9.44M
Total debt$13.27M$13.22M$13.17M$13.12M$13.08M$13.03M$12.99M$13.49M
Total liabilities$34.90M$33.28M$33.73M$34.81M$34.98M$34.43M$35.39M$36.38M
Shareholders' equity$59.78M$62.60M$64.92M$68.78M$72.65M$76.06M$78.61M$82.39M
Net debt$6.64M$7.21M$8.86M$7.21M$9.87M$9.76M$9.61M$9.78M
Shares outstanding53.70M53.68M53.61M53.56M53.52M53.51M53.44M53.41M
Cash flow statement
Operating cash flow-$1.28M-$471,000-$3.36M-$462,000-$1.98M-$2.10M-$4.10M-$936,000
Capital expenditure$120,000$125,000$221,000$348,000$387,000$207,000$206,000$567,000
Free cash flow-$1.40M-$596,000-$3.58M-$810,000-$2.37M-$2.31M-$4.31M-$1.50M
Investing cash flow$1.46M$1.95M$1.84M$3.21M$1.64M$2.03M$3.82M-$1.41M
Financing cash flow$449,000$224,000-$88,000-$37,000$268,000-$28,000-$52,000-$87,000
Depreciation & amortization$1.30M$1.30M$1.58M$1.58M$1.30M$1.30M$1.58M$1.65M
Stock-based compensation$612,000$622,000$695,000$777,000$850,000$950,000$950,000$766,000

Free plan shows the latest 8 periods; Pro shows all 26 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.